New data unveiled at the 10th European AIDS Clinical Society conference provide further evidence that Boehringer Ingelheim’s newly approved anti-HIV drug Aptivus (tipranavir) offers a lasting benefit for patients resistant to other therapies.
Findings from the RESIST-1 and RESIST-2 trials show that Aptivus, a novel non-peptidic protease inhibitor which received a regulatory green light in October, continues to beat several of its commonly-used peers by achieving greater decreases in viral load and greater increases in immune cells through 48 weeks of therapy. In addition, study results also indicate that earlier treatment with the drug leads to better patient outcomes, regardless of the number of protease inhibitors patients had taken previously.
“The availability of Aptivus provides new hope for patients whose virus does not respond well to other anti-HIV drugs,” commented Dr Juergen Rockstroh, professor of medicine and head of the HIV Outpatient Clinic at the University of Bonn in Germany. “Aptivus enables physicians to once again provide convincing treatment against HIV for these patients with limited treatment options,” he added.
